Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

I Chen, K L Wind, C Dehlendorff, B S Sørensen, B V Vittrup, A Johansen, P Pfeiffer, J K Bjerregaard, S E Bojesen, S E Nielsen, N H Holländer, M K Yilmaz, L S Rasmussen, N Pallisgaard, J S Johansen, K-L G Spindler

Research output: Contribution to journalConference abstract in journalResearchpeer-review

2 Citations (Scopus)

Abstract

Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.
Original languageEnglish
Article number715P
JournalAnnals of Oncology
Volume29
Issue numbersuppl_8
Pages (from-to)vii241-vii242
Number of pages2
ISSN0923-7534
DOIs
Publication statusPublished - Oct 2018
EventESMO 2018 Congress (European Society for Medical Oncology): Securing access to optimal cancer care - München, Germany
Duration: 19 Oct 201823 Oct 2018
http://www.esmo.org/Conferences/ESMO-2018-Congress

Conference

ConferenceESMO 2018 Congress (European Society for Medical Oncology)
CountryGermany
CityMünchen
Period19/10/201823/10/2018
Internet address

Cite this

Chen, I., Wind, K. L., Dehlendorff, C., Sørensen, B. S., Vittrup, B. V., Johansen, A., ... Spindler, K-L. G. (2018). Clinical utility of plasma cell-free DNA in patients with pancreatic cancer. Annals of Oncology, 29(suppl_8), vii241-vii242. [715P]. https://doi.org/10.1093/annonc/mdy282.098
Chen, I ; Wind, K L ; Dehlendorff, C ; Sørensen, B S ; Vittrup, B V ; Johansen, A ; Pfeiffer, P ; Bjerregaard, J K ; Bojesen, S E ; Nielsen, S E ; Holländer, N H ; Yilmaz, M K ; Rasmussen, L S ; Pallisgaard, N ; Johansen, J S ; Spindler, K-L G. / Clinical utility of plasma cell-free DNA in patients with pancreatic cancer. In: Annals of Oncology. 2018 ; Vol. 29, No. suppl_8. pp. vii241-vii242.
@article{223ae55883634d4f9b6d0836044a2717,
title = "Clinical utility of plasma cell-free DNA in patients with pancreatic cancer",
abstract = "Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\{\%} confidence intervals (CIs) were estimated by Cox proportional hazards regression.",
author = "I Chen and Wind, {K L} and C Dehlendorff and S{\o}rensen, {B S} and Vittrup, {B V} and A Johansen and P Pfeiffer and Bjerregaard, {J K} and Bojesen, {S E} and Nielsen, {S E} and Holl{\"a}nder, {N H} and Yilmaz, {M K} and Rasmussen, {L S} and N Pallisgaard and Johansen, {J S} and Spindler, {K-L G}",
year = "2018",
month = "10",
doi = "10.1093/annonc/mdy282.098",
language = "English",
volume = "29",
pages = "vii241--vii242",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "suppl_8",

}

Chen, I, Wind, KL, Dehlendorff, C, Sørensen, BS, Vittrup, BV, Johansen, A, Pfeiffer, P, Bjerregaard, JK, Bojesen, SE, Nielsen, SE, Holländer, NH, Yilmaz, MK, Rasmussen, LS, Pallisgaard, N, Johansen, JS & Spindler, K-LG 2018, 'Clinical utility of plasma cell-free DNA in patients with pancreatic cancer', Annals of Oncology, vol. 29, no. suppl_8, 715P, pp. vii241-vii242. https://doi.org/10.1093/annonc/mdy282.098

Clinical utility of plasma cell-free DNA in patients with pancreatic cancer. / Chen, I; Wind, K L; Dehlendorff, C; Sørensen, B S; Vittrup, B V; Johansen, A; Pfeiffer, P; Bjerregaard, J K; Bojesen, S E; Nielsen, S E; Holländer, N H; Yilmaz, M K; Rasmussen, L S; Pallisgaard, N; Johansen, J S; Spindler, K-L G.

In: Annals of Oncology, Vol. 29, No. suppl_8, 715P, 10.2018, p. vii241-vii242.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

TY - ABST

T1 - Clinical utility of plasma cell-free DNA in patients with pancreatic cancer

AU - Chen, I

AU - Wind, K L

AU - Dehlendorff, C

AU - Sørensen, B S

AU - Vittrup, B V

AU - Johansen, A

AU - Pfeiffer, P

AU - Bjerregaard, J K

AU - Bojesen, S E

AU - Nielsen, S E

AU - Holländer, N H

AU - Yilmaz, M K

AU - Rasmussen, L S

AU - Pallisgaard, N

AU - Johansen, J S

AU - Spindler, K-L G

PY - 2018/10

Y1 - 2018/10

N2 - Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

AB - Background: Reliable biomarkers in patients (pts) with pancreatic cancer (PC) are highly warranted. The aim of this prospective-retrospective biomarker study was to investigate the clinical value of cell-free DNA (cfDNA) in pts with PC.Methods: A total of 377 consecutive pts with histologically confirmed PC and 94 healthy controls were included. Total cfDNA levels were determined by a direct fluorescent assay in EDTA plasma samples obtained before operation (stage I and II) or start of palliative chemotherapy (stage III and IV). Serum CA19-9 (IMMULITE 2000, Siemens), hyaluronic acid (HA) (ELISA, R\amp;D), interleukin-6 (IL-6) (ELISA, R\amp;D) and YKL-40 (ELISA, Quidel) were measured. The main outcome was association of cfDNA with overall survival (OS) for pts with PC. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

U2 - 10.1093/annonc/mdy282.098

DO - 10.1093/annonc/mdy282.098

M3 - Conference abstract in journal

VL - 29

SP - vii241-vii242

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - suppl_8

M1 - 715P

ER -

Chen I, Wind KL, Dehlendorff C, Sørensen BS, Vittrup BV, Johansen A et al. Clinical utility of plasma cell-free DNA in patients with pancreatic cancer. Annals of Oncology. 2018 Oct;29(suppl_8):vii241-vii242. 715P. https://doi.org/10.1093/annonc/mdy282.098